Current cancer immunotherapies are primarily predicated on αβ T cells, with a stringent
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …

γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen
presentation, which makes them a highly promising effector cell compartment for cancer …

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly
require the presence of αβT cells that recognize tumour neoantigens, and are therefore …

While most studies of T lymphocytes have focused on T cells reactive to complexes of
peptide and major histocompatibility complex (MHC) proteins, many other types of T cells do …

T lymphocytes comprise cells expressing either an αβ or a γδ TCR. The riddle how αβ TCRs
are triggered by specific peptides presented in the context of MHC was elucidated some …

Background γδ T cells are a distinct subgroup of T cells containing T cell receptors (TCRs) γ
and TCR δ chains with diverse structural and functional heterogeneity. As a bridge between …

The hepatic immune system is constantly exposed to a massive load of harmless dietary and
commensal antigens, to which it must remain tolerant. Immune tolerance in the liver is …

While the effector cells that mediate anti-tumor immunity have historically been attributed to
αβ T cells and natural killer cells, γδ T cells are now being recognized as a complementary …

A growing number of studies have shown that γδ T cells play a pivotal role in mediating the
clearance of tumors and pathogen-infected cells with their potent cytotoxic, cytolytic, and …